Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,007 stopped studies mapped to B-Cell Non-Hodgkin Lymphoma and descendants · 89% state a reason
Over the 1,007 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00003511 | Antineoplaston Therapy in Treating Patients With Multiple Myeloma | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | Slow accrual | Enrollment / accrual |
| NCT03579888 | CD19-Specific T Cells Post AlloSCT | Phase 1 | terminated | Jul 9, 2018 | M.D. Anderson Cancer Center | Study halted prematurely | Other (stated, no rule matched) |
| NCT03910439 | Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed… | Phase 2 | terminated | Apr 10, 2019 | National Cancer Institute (NCI) | Slow/Insufficient accrual/COVID-19 pandemic | COVID-19 / pandemic |
| NCT01999335 | A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory… | Phase 1 | terminated | Dec 3, 2013 | Amgen | A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of… | Safety / toxicity |
| NCT01125293 | Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory… | Phase 1 / Phase 2 | terminated | May 18, 2010 | Dana-Farber Cancer Institute | Per protocol, Phase II is to be terminated early if a less than 5% of the Phase II participants… | Enrollment / accrual |
| NCT01079429 | Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma…(GENOMGUS) | — | terminated | Mar 3, 2010 | Rennes University Hospital | sponsor and investigator 's decision | Investigator |
| NCT02036502 | A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in… | Phase 1 | terminated | Jan 15, 2014 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT01678443 | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With… | Phase 1 | terminated | Sep 5, 2012 | Fred Hutchinson Cancer Center | Terminated due to low accrual. | Enrollment / accrual |
| NCT03340883 | Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple… | Phase 1 / Phase 2 | terminated | Nov 14, 2017 | Chinook Therapeutics, Inc. | No objective responses observed following completion of Phase 1 dose-escalation | Other (stated, no rule matched) |
| NCT02576275 | A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in… | Phase 3 | withdrawn | Oct 15, 2015 | SecuraBio | The scope of the program has been reduced to focus resources on studies which can potentially… | Other (stated, no rule matched) |
| NCT04342117 | Observational Trial of Real-World Treatment Utilization and Effectiveness of…(REAL) | — | terminated | Apr 10, 2020 | SecuraBio | Strategy Change | Sponsor / business decision |
| NCT03440411 | Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During…(PO-3887) | Phase 3 | terminated | Feb 22, 2018 | Fondazione EMN Italy Onlus | Low enrollment | Enrollment / accrual |
| NCT01109407 | Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and… | — | terminated | Apr 23, 2010 | National Cancer Institute (NCI) | PI Left before primary outcome was established | Investigator |
| NCT00437034 | Aflibercept for Relapsed Multiple Myeloma | Phase 2 | terminated | Feb 19, 2007 | National Cancer Institute (NCI) | Poor accrual | Enrollment / accrual |
| NCT00176930 | Stem Cell Transplant for Hematological Malignancy | N/A | terminated | Sep 15, 2005 | Masonic Cancer Center, University of Minnesota | replaced by another study ; Trial re-written as MT2015-29 | Other (stated, no rule matched) |
| NCT03601819 | Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders | Phase 1 | terminated | Jul 26, 2018 | University of Michigan Rogel Cancer Center | Low accrual | Enrollment / accrual |
| NCT02309515 | Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic… | Phase 2 | terminated | Dec 5, 2014 | Mayo Clinic | Slow Accrual | Enrollment / accrual |
| NCT03512353 | A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple… | Phase 2 | terminated | Apr 30, 2018 | Amgen | Sponsor Decision | Sponsor / business decision |
| NCT03205046 | A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell… | Phase 1 / Phase 2 | terminated | Jul 2, 2017 | Acerta Pharma BV | Sponsor's decision not to pursue further development of the combination in DLBCL | Sponsor / business decision |
| NCT01402440 | Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large… | Phase 1 | terminated | Jul 26, 2011 | Novartis Pharmaceuticals | Study terminated due to enrolment challenges and availability of other options for DLBCL patients.… | Safety / toxicity |
| NCT01643603 | Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic… | Phase 1 | terminated | Jul 18, 2012 | Barbara Ann Karmanos Cancer Institute | Study terminated due to slow accrual. | Enrollment / accrual |
| NCT02951156 | Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator,…(Javelin DLBCL) | Phase 3 | terminated | Nov 1, 2016 | Pfizer | Study was terminated due to closure of study arms following futility analysis and difficulty in… | Efficacy / futility |
| NCT03739606 | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer | Phase 2 | withdrawn | Nov 14, 2018 | City of Hope Medical Center | RSS recommendation | Other (stated, no rule matched) |
| NCT01121120 | Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell…(TXA127-PBSC) | Phase 2 | terminated | May 12, 2010 | Tarix Pharmaceuticals | not stated | Not stated |
| NCT03117361 | Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in… | Phase 2 | terminated | Apr 17, 2017 | PharmaMar | PharmaMar has decided to end this study due to the slow recruitment rate of the trial | Enrollment / accrual |
| NCT02151903 | Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in… | Phase 1 / Phase 2 | terminated | Jun 2, 2014 | Alopexx Oncology, LLC | Clinical benefit was noted before the scheduled completion of the trial and the extension study was… | Other (stated, no rule matched) |
| NCT01874288 | A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With…(DI-Leu16-IL2) | Phase 1 / Phase 2 | terminated | Jun 11, 2013 | Alopexx Oncology, LLC | Clinical benefit was noted in the earlier portion of the trial; hence, participants were not… | Enrollment / accrual |
| NCT02483000 | Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating… | Phase 1 | terminated | Jun 26, 2015 | Fred Hutchinson Cancer Center | Closed early due to lack of funding | Funding |
| NCT01799889 | Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib… | Phase 2 | terminated | Feb 27, 2013 | Gilead Sciences | Sponsor's decision to discontinue development of entospletinib. | Sponsor / business decision |
| NCT02897830 | Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus…(IFM2014-03) | Phase 2 | terminated | Sep 13, 2016 | University Hospital, Toulouse | negatives results | Other (stated, no rule matched) |
| NCT04621955 | Observational Study of Home Administration of Carfilzomib(KARE-2) | — | withdrawn | Nov 9, 2020 | Universitaire Ziekenhuizen KU Leuven | Not possible to conduct study | Other (stated, no rule matched) |
| NCT03033316 | A Evaluation of the Safety of Oncocort IV Pegylated Liposomal Dexamethasone Phosphate in…(AMETHYST) | Phase 1 / Phase 2 | terminated | Jan 26, 2017 | Enceladus Pharmaceuticals BV | Patient enrolment issues | Enrollment / accrual |
| NCT04094766 | Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R… | Phase 1 | withdrawn | Sep 19, 2019 | Second Affiliated Hospital of Xi'an Jiaotong University | Production plan adjustment | Other (stated, no rule matched) |
| NCT03287804 | APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma(APRIL) | Phase 1 / Phase 2 | terminated | Sep 19, 2017 | Autolus Limited | Preliminary efficacy seen to date following treatment with AUTO2 has been determined not sufficient… | Efficacy / futility |
| NCT04503538 | Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity | N/A | withdrawn | Aug 7, 2020 | Wake Forest University Health Sciences | Principal investigator decided not to pursue trial | Investigator |
| NCT03779555 | Lenalidomide Adherence in Older Adults | — | terminated | Dec 19, 2018 | Washington University School of Medicine | Principal Investigator left the university | Investigator |
| NCT02012231 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in… | Phase 1 | terminated | Dec 16, 2013 | Fore Biotherapeutics | not stated | Not stated |
| NCT03037645 | Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers | Phase 1 / Phase 2 | terminated | Jan 31, 2017 | Sunesis Pharmaceuticals | Phase 1b portion completed. Sponsor decided not to proceed with P2 portion of study. Vecabrutinib… | Sponsor / business decision |
| NCT03963024 | Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT(TrRaMM-TMI) | Phase 1 | terminated | May 24, 2019 | IRCCS San Raffaele | low rate of enrolment | Enrollment / accrual |
| NCT04293900 | Diet, Physical Activity and Body Composition Changes During R-CHOP(R-CHOP-OS) | — | withdrawn | Mar 3, 2020 | George Washington University | Study never started due to COVID pandemic and lack of study funding. | COVID-19 / pandemic |
| NCT02786485 | Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After… | Phase 1 | withdrawn | Jun 1, 2016 | Bellicum Pharmaceuticals | not stated | Not stated |
| NCT02991898 | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | Phase 2 | terminated | Dec 14, 2016 | Masonic Cancer Center, University of Minnesota | Considering new technology for product. | Other (stated, no rule matched) |
| NCT03925428 | Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and… | Phase 1 | withdrawn | Apr 24, 2019 | National Cancer Institute (NCI) | Other - Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT02952573 | Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back… | Phase 2 | terminated | Nov 2, 2016 | University Health Network, Toronto | Low patient accrual | Enrollment / accrual |
| NCT03225924 | Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by… | Phase 1 / Phase 2 | terminated | Jul 21, 2017 | The Lymphoma Academic Research Organisation | Stop of drug development | Other (stated, no rule matched) |
| NCT01460602 | Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and… | Phase 1 / Phase 2 | withdrawn | Oct 27, 2011 | Louisiana State University Health Sciences Center Shreveport | Investigator has relocated to MD Anderson | Investigator |
| NCT03000660 | Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL… | Phase 1 | terminated | Dec 22, 2016 | Tufts Medical Center | partial clinical hold per FDA | Other (stated, no rule matched) |
| NCT04355039 | INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple… | Phase 1 | withdrawn | Apr 21, 2020 | Medical College of Wisconsin | Terminated for lack of funding. | Funding |
| NCT00674427 | Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After… | Phase 1 | terminated | May 7, 2008 | University of Pennsylvania | Insufficient funds | Funding |
| NCT01973062 | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System… | Phase 2 | terminated | Oct 31, 2013 | Case Comprehensive Cancer Center | Funding Unavailable | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jun 9, 2021source: clinicaltrials